Skye Bioscience マネジメント

マネジメント基準チェック /14

Skye Bioscienceの CEO はPunit Dhillonで、 Aug2020年に任命され、の在任期間は 4.25年です。の年間総報酬は$ 1.81Mで、 24.9%給与と75.1%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の1.12%を直接所有しており、その価値は$ 1.44M 。経営陣と取締役会の平均在任期間はそれぞれ2.5年と0.7年です。

主要情報

Punit Dhillon

最高経営責任者

US$1.8m

報酬総額

CEO給与比率	24.9%
CEO在任期間	4.3yrs
CEOの所有権	1.1%
経営陣の平均在職期間	2.5yrs
取締役会の平均在任期間	less than a year

経営陣の近況

Recent updates

Skye: Moving Weight Loss Drugs To The Next Level

Sep 04

Is Skye Bioscience (NASDAQ:SKYE) Using Debt In A Risky Way?

Aug 11

CEO報酬分析

Skye Bioscience の収益と比較して、Punit Dhillon の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$21m
Jun 30 2024	n/a	n/a	-US$42m
Mar 31 2024	n/a	n/a	-US$37m
Dec 31 2023	US$2m	US$450k	-US$38m
Sep 30 2023	n/a	n/a	-US$43m
Jun 30 2023	n/a	n/a	-US$21m
Mar 31 2023	n/a	n/a	-US$22m
Dec 31 2022	US$668k	US$433k	-US$19m
Sep 30 2022	n/a	n/a	-US$12m
Jun 30 2022	n/a	n/a	-US$11m
Mar 31 2022	n/a	n/a	-US$9m
Dec 31 2021	US$900k	US$400k	-US$9m
Sep 30 2021	n/a	n/a	-US$8m
Jun 30 2021	n/a	n/a	-US$7m
Mar 31 2021	n/a	n/a	-US$6m
Dec 31 2020	US$615k	US$160k	-US$7m
Sep 30 2020	n/a	n/a	-US$207k
Jun 30 2020	n/a	n/a	-US$4m
Mar 31 2020	n/a	n/a	US$13m
Dec 31 2019	US$65k	n/a	US$1m
Sep 30 2019	n/a	n/a	-US$10m
Jun 30 2019	n/a	n/a	-US$7m
Mar 31 2019	n/a	n/a	-US$26m
Dec 31 2018	US$82k	n/a	-US$19m

報酬と市場: Punitの総報酬 ($USD 1.81M ) は、 US市場 ($USD 642.87K ) の同規模の企業の平均を上回っています。

報酬と収益: Punitの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Punit Dhillon (44 yo)

4.3yrs

在職期間

US$1,807,338

報酬

Mr. Punit S. Dhillon, BA, has been Chief Executive Officer of Skye Bioscience, Inc. since August 10, 2020. Mr. Dhillon serves as Chair of Skye Bioscience, Inc. until October 25, 2024. He served as Principa...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Punit Dhillon	President	4.3yrs	US$1.81m	1.12% $ 1.4m
Kaitlyn Arsenault	Chief Financial Officer	3.1yrs	US$1.27m	0.55% $ 708.6k
Christopher Twitty	Chief Scientific Officer	1.9yrs	データなし	データなし
Tu Diep	Chief Development Officer	no data	データなし	0.27% $ 350.4k
Puneet Arora	Chief Medical Officer	less than a year	データなし	データなし

2.5yrs

平均在職期間

43.5yo

平均年齢

経験豊富な経営陣: SKYEの経営陣は経験豊富であると考えられます ( 2.5年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Punit Dhillon	President	6.8yrs	US$1.81m	1.12% $ 1.4m
Paul Grayson	Independent Chairman of the Board	1.3yrs	US$1.25m	0.86% $ 1.1m
Andrew Schwab	Director	1.3yrs	US$74.08k	0% $ 0
Louis Aronne	Member of Clinical & Scientific Advisory Board	less than a year	データなし	データなし
Annalisa Lisa Jenkins	Independent Director	less than a year	データなし	0% $ 0
Karen Smith	Director	less than a year	データなし	0% $ 0
Deborah Charych	Independent Director	1.8yrs	US$102.28k	0% $ 0
Rekha Kumar	Member of Clinical & Scientific Advisory Board	less than a year	データなし	データなし
Lee Kaplan	Member of Clinical & Scientific Advisory Board	less than a year	データなし	データなし
Beverly Tchang	Member of Clinical & Scientific Advisory Board	less than a year	データなし	データなし
Marcus Goncalves	Member of Clinical & Scientific Advisory Board	less than a year	データなし	データなし

0.7yrs

平均在職期間

59yo

平均年齢

経験豊富なボード: SKYEの取締役会は経験豊富ではない ( 0.7年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Skye Bioscience マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Skye Bioscience Names Paul Grayson as Chairman of the Board

Skye Bioscience, Inc. Appoints Puneet S. Arora as Chief Medical Officer

Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab

Skye Bioscience, Inc. Appoints Dr. Karen Smith to Board of Directors, Effective August 1, 2024

High number of new directors

Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors

Recent updates

Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated Cb1 Inhibitor

Skye Bioscience Demonstrates Prominent Role of Peripheral Cb1 Inhibition and Achieves Significant Weight Loss with Novel Cb1-Inhibiting Antibody, Nimacimab, in Preclinical Model

Skye Bioscience, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Skye Bioscience Names Paul Grayson as Chairman of the Board

Skye Bioscience, Inc.(NasdaqGM:SKYE) dropped from NASDAQ Transportation Index

Skye Bioscience, Inc.(NasdaqGM:SKYE) dropped from NASDAQ Transportation Index

Skye: Moving Weight Loss Drugs To The Next Level

Skye Bioscience, Inc. Appoints Puneet S. Arora as Chief Medical Officer

Skye Bioscience, Inc. Launches Phase 2 Cbeyond Clinical Trial of Its Differentiated Cb1 Inhibitor, Nimacimab, in Patients with Obesity

Is Skye Bioscience (NASDAQ:SKYE) Using Debt In A Risky Way?

Skye Bioscience, Inc. Announces Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints

Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab

Skye Bioscience, Inc. Appoints Dr. Karen Smith to Board of Directors, Effective August 1, 2024

Skye Bioscience, Inc. Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program

Skye Bioscience, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Revenue and earnings growth

High number of new directors

Skye Bioscience, Inc. announced that it has received $40 million in funding from 5AM Venture Management, LLC

Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors

Skye Bioscience Completes Enrollment of Phase 2A Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension

Skye Bioscience, Inc. announced that it has received $49.99101 million in funding

Skye Bioscience, Inc. announced that it expects to receive $50.249992 million in funding

Skye Bioscience, Inc. Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, Nimacimab

Skye Bioscience, Inc. Announces Board Appointments

New major risk - Share price stability

Skye Bioscience, Inc. Appoints Deborah Charych to Board of Directors

Skye Bioscience Announces First-in-Human Phase 1 Trial of Proprietary Cannabinoid Derivative and Nanoemulsion Formulation Designed to Potentially Treat Glaucoma

Skye Bioscience, Inc. Appoints Rai as Member of the Nominating and Corporate Governance Committee of the Board

Skye Bioscience, Inc. Appoints Chris Twitty as Chief Scientific Officer

Skye Bioscience, Inc. (OTCPK:SKYE) completed the acquisition of Emerald Health Therapeutics, Inc. (CNSX:EMH) from Emerald Health Sciences Inc. and others.

Skye Bioscience, Inc. Completes Drug Production for Phase 1 Clinical Study

Skye Bioscience, Inc. Updates Phase 1 Timeline

Skye Bioscience, Inc. Announces Resignation of Jim Heppell as A Member of Board of Directors, Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee

Skye Bioscience, Inc. (OTCPK:SKYE) entered into a definitive agreement to acquire Emerald Health Therapeutics, Inc. (CNSX:EMH) for CAD 21.7 million.

Skye Bioscience, Inc. Reports Positive Results for SBI-100 in GLP Toxicology Study

Skye Bioscience, Inc. Reports Potential Neuroprotective Benefit of SBI-100 in Preclinical Glaucoma Model

Skye Bioscience Announces THCVHS Late-Breaking Preclinical Abstracts Selected by American Association of Pharmaceutical Scientists Meeting PharmSci 360

Skye Bioscience’s THCVHS Demonstrates Superior Therapeutic Benefit Compared to Glaucoma Standard of Care, Both as Combination and Single Agent, in Preclinical Study

Skye Bioscience, Inc. Announces Board Appointments

Emerald Bioscience Inc., Annual General Meeting, Jan 28, 2021

Emerald Bioscience Inc. Provides an Update on Progress across its Product Pipeline, including adjusted clinical milestones

Emerald Bioscience Inc. Announces Changes in Principal Financial Officer

Emerald Bioscience Inc. Announces Executive Changes

Emerald Bioscience Inc. has completed a Composite Units Offering in the amount of $6.939667 million.

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /14